FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Oncology Drugs in Phase I Clinical Development in CHINA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BGB-3245

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 27, 2020

            Details:

            The Phase 1 clinical trial is a first-in-human study to investigate the safety, pharmacokinetics and antitumor activity of BGB-3245 in adult patients with solid tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Niraparib

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 04, 2020

            Details:

            Phase 1b study of Niraparib in combination with MGD013 in advanced or metastatic gastric cancer in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SCB-313

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and efficacy of intrapleural administered SCB-313 for the treatment of MPE.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adg106

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: General Atlantic

            Deal Size: $69.0 million Upfront Cash: Undisclosed

            Deal Type: Series D Financing January 08, 2020

            Details:

            Proceeds will support advancement of lead immunotherapy clinical programs ADG106 and extend the frontiers of novel technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IN10018,Pembrolizumab

            Therapeutic Area: Oncology

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2020

            Details:

            InxMed will be the study sponsor and MSD will provide pembrolizumab to InxMed to use in the clinical study. This is the first global clinical collaboration between the two companies.